Author Guidelines
SCOPE
The Annals of Clinical and Translational Neurology (ACTN) publishes articles of broad interest with potential for high impact in understanding the mechanisms and treatment of diseases of the human nervous system. All areas of clinical and basic neuroscience, including new technologies, cellular and molecular neurobiology, population sciences, and studies of behavior, addiction, and psychiatric diseases are of interest to the journal. ACTN is particularly interested in clinical trials and other large-scale studies that inform the practice of medicine. Trials reporting negative data will be considered. The scope of ACTN also includes topics of particular significance in neurologic education as well as other topics of interest to the clinical neuroscience community. In addition to manuscripts from established investigators, ACTN will welcome scholarly work, points-of-view, and case studies from residents, fellows and medical students.
EDITORIAL POLICIES
Contact
To ensure that your communications for all other matters are properly routed to the appropriate Editors, correspondence regarding your submission must be directed to Emily Hammond, Managing Editor at ACTNedoffice@wiley.com. Do not contact the Editor-in-Chief, Associate Editors, or members of the Editorial Board.
General
Submissions must not be under consideration by any other journal or published previously (apart from abstracts).
Ethical Compliance
Experimental studies of human subjects require that the protocol has received prior approval by the appropriate institutional review board, and that informed consent was obtained from each subject. This approval must be noted in the Methods.
Animal experimentation must receive institutional approval and be conducted in accordance with the United States Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and this approval must be stated in the Methods. States must include evidence that human and animal research complies with the standards enforced in the country of origin.
We require documentation of either human subjects or animal protocol approval at the time a paper is submitted. Authors should upload this in the system with the designation, “Additional File NOT for Review and NOT for Publication”.
Following publication authors will be required to make available any new nucleic acid constructs, recombinant organisms, antibodies, or other unique reagents and to make their data available to other investigators for the purpose of verifying and replicating results. The Editors strongly encourage authors to make their data available to other investigators for other purposes, e.g., to deposit microarray data in a public repository, such as GEO or ArrayExpress.
Clinical Trials
Although ACTN does not advocate one particular registry, clinical trials must be registered in a database that meets the requirements set forth by the ICMJE: (1) The registry must be publicly accessible. (2) It must be open to all registrants and managed by a not-for-profit group. (3) The registry must have a mechanism to guarantee accuracy and validity of the information submitted. (4) The registry must adhere to the ICMJE mandates described at their website: http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. Additional information can be found at: http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/
Clinical trial reports must be written in accordance with the CONSORT reporting guidelines.
Credits and Permissions
Upon acceptance, we will require (1) notice of informed consent; (2) releases to publish photographs of recognizable persons; and (3) written permission to use non-original material (including quotations exceeding 100 words or any table / figure) from both author and publisher of the original material. No article will be published without all required permissions. Credit the source in a text or table footnote, or in a legend.
Conflict of interest
ACTN is compliant with the International Committee of Medical Journal Editors (ICMJE) recommendations regarding conflict of interest disclosures. All authors are required to report the following information with each submission: (1) Financial associations with commercial entities that provided financial support for the work reported in the submitted manuscript. The time frame for this disclosure covers the duration of the work itself, from conception and planning to the present. (2) Financial associations with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript. All sources of revenue relevant to the submitted work that accrued either directly to you or to your institution on your behalf should be disclosed. The time frame for this disclosure covers the 36 months prior to submission of the manuscript. (3) Financial associations involving spouses or children under 18 years of age. (4) Non-financial associations that may be perceived as relevant to the submitted manuscript, including personal, professional, political, institutional, religious, or other associations that may be perceived as relevant. This information will be acknowledged at publication. Rejection of a manuscript or retraction may occur if undisclosed financial interests are found after publication.
ACTN requires that authors follow the International Committee of Medical Journal Editors (ICMJE) "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals."
ACTN complies with the International Committee of Medical Journal Editors (ICMJE) recommendations regarding conflicts of interest. Relevant information and a copy of the necessary information can be obtained at: www.icmje.org/coi_disclosure.pdf
Publication fees
Publication fees can be found here. Note that the discounts listed on this page are all-inclusive; special exceptions and discounts cannot be negotiated. Information about specific funder policies is available here.
Transfers from Annals of Neurology
ACTN often provides rapid review of submissions that its sister journal, Annals of Neurology is unable to publish due to space or priority. Authors of such papers will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of ACTN. If reviewers have already comments on the paper, authors will be required to revise and respond to those comments at the time of transfer, which will improve the turnaround time to decision. Although there is no strict deadline for completing a transfer, the journal generally prefers to receive transfers within six months of decision in Annals.
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/23289503/homepage/forauthors.html
